Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since August 6, 2021.

Common Stock Valuation Ratios (Price Multiples) 

Microsoft Excel

Current Valuation Ratios

Boston Scientific Corp., current price multiples

Microsoft Excel
Boston Scientific Corp. Abbott Laboratories Bristol-Myers Squibb Co. Cigna Corp. CVS Health Corp. Danaher Corp. Elevance Health Inc. Humana Inc. Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc. Health Care Equipment & Services Health Care
Selected Financial Data
Current share price (P) $44.70
No. shares of common stock outstanding 1,423,852,648
 
Earnings per share (EPS) $-0.08
Operating profit per share $-0.06
Sales per share $6.96
Book value per share (BVPS) $10.76
Valuation Ratios (Price Multiples)
Price to sales (P/S) 6.42 4.05 3.25 0.51 0.44 6.64 0.82 0.76 12.09 3.47 1.69 1.55 2.59
Price to book value (P/BV) 4.15 4.87 4.19 1.86 1.71 4.33 3.13 3.93 5.80 2.09 6.72 3.90 5.48

Based on: 10-K (reporting date: 2020-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Boston Scientific Corp., historical price multiples

Microsoft Excel
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Price to earnings (P/E) 11.86 33.06 354.70 96.19
Price to operating profit (P/OP) 36.71 36.68 28.71 74.67
Price to sales (P/S) 5.54 5.19 5.62 4.08 3.98
Price to book value (P/BV) 3.58 4.02 6.33 5.26 4.96

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 not reaching 2018 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio decreased from 2018 to 2019 and from 2019 to 2020.

Price to Earnings (P/E)

Boston Scientific Corp., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 1,417,165,707 1,396,195,349 1,385,961,926 1,374,910,797 1,363,488,640
Selected Financial Data (US$)
Net income (loss) available to common stockholders (in millions) (115) 4,700  1,671  104  347 
Earnings per share (EPS)2 -0.08 3.37 1.21 0.08 0.25
Share price1, 3 38.75 39.91 39.86 26.83 24.48
Valuation Ratio
P/E ratio4 11.86 33.06 354.70 96.19
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 48.49 41.83 56.47 220.29
Bristol-Myers Squibb Co. 41.99 16.81 103.55
Cigna Corp. 8.71 13.26 25.14 21.27
CVS Health Corp. 12.88 14.15 10.69
Danaher Corp. 44.49 38.34 29.77 27.25
Elevance Health Inc. 15.87 15.96 21.45 15.44
Humana Inc. 14.48 18.10 24.77 15.13
Intuitive Surgical Inc. 87.47 48.72 53.03 70.95
Medtronic PLC 26.30 28.78 37.80 29.96
UnitedHealth Group Inc. 20.54 20.48 21.09 20.77
P/E Ratio, Sector
Health Care Equipment & Services 30.38 24.05 29.40 25.57
P/E Ratio, Industry
Health Care 29.25 21.33 26.37 30.16

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
EPS = Net income (loss) available to common stockholders ÷ No. shares of common stock outstanding
= -115,000,000 ÷ 1,417,165,707 = -0.08

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2020 Calculation
P/E ratio = Share price ÷ EPS
= 38.75 ÷ -0.08 =

5 Click competitor name to see calculations.


Price to Operating Profit (P/OP)

Boston Scientific Corp., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 1,417,165,707 1,396,195,349 1,385,961,926 1,374,910,797 1,363,488,640
Selected Financial Data (US$)
Operating income (loss) (in millions) (80) 1,518  1,506  1,285  447 
Operating profit per share2 -0.06 1.09 1.09 0.93 0.33
Share price1, 3 38.75 39.91 39.86 26.83 24.48
Valuation Ratio
P/OP ratio4 36.71 36.68 28.71 74.67
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 40.69 34.03 36.64 60.88
Bristol-Myers Squibb Co. 24.42 16.16 28.87
Cigna Corp. 9.03 8.38 15.94 12.07
CVS Health Corp. 6.65 7.83 18.65 7.44
Danaher Corp. 36.91 34.47 23.18 22.48
Elevance Health Inc. 12.10 13.55 15.87 14.81
Humana Inc. 9.78 15.35 13.45 8.69
Intuitive Surgical Inc. 88.37 48.89 49.87 44.40
Medtronic PLC 26.29 21.26 17.64 22.64
UnitedHealth Group Inc. 14.12 14.40 14.58 14.42
P/OP Ratio, Sector
Health Care Equipment & Services 21.57 16.90 18.41 17.00
P/OP Ratio, Industry
Health Care 22.12 17.16 19.00 18.03

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= -80,000,000 ÷ 1,417,165,707 = -0.06

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 38.75 ÷ -0.06 =

5 Click competitor name to see calculations.


Price to Sales (P/S)

Boston Scientific Corp., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 1,417,165,707 1,396,195,349 1,385,961,926 1,374,910,797 1,363,488,640
Selected Financial Data (US$)
Net sales (in millions) 9,913  10,735  9,823  9,048  8,386 
Sales per share2 6.99 7.69 7.09 6.58 6.15
Share price1, 3 38.75 39.91 39.86 26.83 24.48
Valuation Ratio
P/S ratio4 5.54 5.19 5.62 4.08 3.98
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 6.30 4.83 4.37 3.84
Bristol-Myers Squibb Co. 3.16 5.52 3.67 5.02
Cigna Corp. 0.46 0.44 1.41 1.17
CVS Health Corp. 0.35 0.37 0.39 0.38
Danaher Corp. 7.01 6.29 3.97 3.70
Elevance Health Inc. 0.60 0.74 0.88 0.67
Humana Inc. 0.64 0.76 0.74 0.69
Intuitive Surgical Inc. 21.29 15.01 16.06 14.97
Medtronic PLC 4.36 4.36 3.92 4.06
UnitedHealth Group Inc. 1.24 1.18 1.12 1.10
P/S Ratio, Sector
Health Care Equipment & Services 1.32 1.28 1.37 1.32
P/S Ratio, Industry
Health Care 2.21 2.07 2.27 2.23

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
Sales per share = Net sales ÷ No. shares of common stock outstanding
= 9,913,000,000 ÷ 1,417,165,707 = 6.99

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 38.75 ÷ 6.99 = 5.54

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 not reaching 2018 level.

Price to Book Value (P/BV)

Boston Scientific Corp., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
No. shares of common stock outstanding1 1,417,165,707 1,396,195,349 1,385,961,926 1,374,910,797 1,363,488,640
Selected Financial Data (US$)
Stockholders’ equity (in millions) 15,326  13,877  8,726  7,012  6,733 
Book value per share (BVPS)2 10.81 9.94 6.30 5.10 4.94
Share price1, 3 38.75 39.91 39.86 26.83 24.48
Valuation Ratio
P/BV ratio4 3.58 4.02 6.33 5.26 4.96
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 6.65 4.96 4.38 3.40
Bristol-Myers Squibb Co. 3.55 2.80 5.89 8.88
Cigna Corp. 1.46 1.49 1.62 3.47
CVS Health Corp. 1.33 1.47 1.29 1.88
Danaher Corp. 3.93 3.72 2.80 2.58
Elevance Health Inc. 2.19 2.42 2.82 2.24
Humana Inc. 3.55 4.07 4.10 3.76
Intuitive Surgical Inc. 9.53 8.13 8.96 9.91
Medtronic PLC 2.48 2.66 2.31 2.40
UnitedHealth Group Inc. 4.83 4.92 4.89 4.59
P/BV Ratio, Sector
Health Care Equipment & Services 3.30 3.10 3.09 3.39
P/BV Ratio, Industry
Health Care 4.67 4.44 4.43 4.20

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Data adjusted for splits and stock dividends.

2 2020 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 15,326,000,000 ÷ 1,417,165,707 = 10.81

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 38.75 ÷ 10.81 = 3.58

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio decreased from 2018 to 2019 and from 2019 to 2020.